Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Tim Green & Troy Green, Tim Green, and Troy Green. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tim Green & Troy Green, Tim Green, and Troy Green or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

#60 - Craig Boyce & Dr. Melanie Leitner: Can Venture Capital Cure ALS?

1:50:17
 
Share
 

Manage episode 478566815 series 3563428
Content provided by Tim Green & Troy Green, Tim Green, and Troy Green. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tim Green & Troy Green, Tim Green, and Troy Green or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

When private-equity veteran Craig Boyce left nearly two decades at Bain Capital and neuroscientist Dr. Melanie Leitner stepped out of the lab, both carried a deeply personal mission: speed up the end of ALS. Together they helm the ALS Investment Fund, a for-profit venture vehicle that backs early-stage therapeutics aimed at turning the disease from terminal to chronically managed by filling the “capital void” between basic research and big-pharma buy-in​.

In this conversation with Tim and Troy, Craig recounts losing his father to ALS and how that tragedy redirected his deal-making skills toward impact investing​, while Melanie shares the “seventh-grade brain report” that launched her career and why today’s biomarker and platform-trial advances finally make true progress possible​. They break down:

  • Why capital markets—not philanthropy alone—must fund $10-$50 M clinical trials ​
  • The business case that’s luring big pharma back to neuro (“the decade of neurodegeneration”) ​
  • How a cystic-fibrosis-style royalty model could recycle billions into ALS research ​
  • The audacious goal to “put ourselves out of business” by making effective therapies commonplace ​

If you’re curious how finance, science, and relentless human stories converge to accelerate cures, this episode delivers a front-row seat.

SPONSORS:

ElevenLabs: Thanks to ElevenLabs (https://elevenlabs.io) for supporting this episode and powering Tim’s voice.

ALS Investment Fund: Thanks to ALS Investment Fund (https://www.alsinvestmentfund.com) for supporting this episode.

SOCIAL:

Website: https://tgnlu.com

Twitter: https://twitter.com/nlutimgreen

Facebook: https://www.facebook.com/NLUpod

Instagram: https://www.instagram.com/nlupod/

AUDIO ONLY:

Spotify: https://open.spotify.com/show/5fhcANt7CSnYvgBlgxpVVa

Apple Podcasts: https://podcasts.apple.com/us/podcast/nothing-left-unsaid/id1734094890

PERSONAL:

Tackle ALS: https://www.tackleals.com

Tim Green Books: https://authortimgreen.com

Learn more about your ad choices. Visit megaphone.fm/adchoices

  continue reading

64 episodes

Artwork
iconShare
 
Manage episode 478566815 series 3563428
Content provided by Tim Green & Troy Green, Tim Green, and Troy Green. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tim Green & Troy Green, Tim Green, and Troy Green or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

When private-equity veteran Craig Boyce left nearly two decades at Bain Capital and neuroscientist Dr. Melanie Leitner stepped out of the lab, both carried a deeply personal mission: speed up the end of ALS. Together they helm the ALS Investment Fund, a for-profit venture vehicle that backs early-stage therapeutics aimed at turning the disease from terminal to chronically managed by filling the “capital void” between basic research and big-pharma buy-in​.

In this conversation with Tim and Troy, Craig recounts losing his father to ALS and how that tragedy redirected his deal-making skills toward impact investing​, while Melanie shares the “seventh-grade brain report” that launched her career and why today’s biomarker and platform-trial advances finally make true progress possible​. They break down:

  • Why capital markets—not philanthropy alone—must fund $10-$50 M clinical trials ​
  • The business case that’s luring big pharma back to neuro (“the decade of neurodegeneration”) ​
  • How a cystic-fibrosis-style royalty model could recycle billions into ALS research ​
  • The audacious goal to “put ourselves out of business” by making effective therapies commonplace ​

If you’re curious how finance, science, and relentless human stories converge to accelerate cures, this episode delivers a front-row seat.

SPONSORS:

ElevenLabs: Thanks to ElevenLabs (https://elevenlabs.io) for supporting this episode and powering Tim’s voice.

ALS Investment Fund: Thanks to ALS Investment Fund (https://www.alsinvestmentfund.com) for supporting this episode.

SOCIAL:

Website: https://tgnlu.com

Twitter: https://twitter.com/nlutimgreen

Facebook: https://www.facebook.com/NLUpod

Instagram: https://www.instagram.com/nlupod/

AUDIO ONLY:

Spotify: https://open.spotify.com/show/5fhcANt7CSnYvgBlgxpVVa

Apple Podcasts: https://podcasts.apple.com/us/podcast/nothing-left-unsaid/id1734094890

PERSONAL:

Tackle ALS: https://www.tackleals.com

Tim Green Books: https://authortimgreen.com

Learn more about your ad choices. Visit megaphone.fm/adchoices

  continue reading

64 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play